The Novel Nutraceutical KJS018A Prevents Hepatocarcinogenesis Promoted by Inflammation

Area of Science:

• Oncology
• Inflammation research
• Pharmacology

Background:

• Inflammation is linked to cancer initiation and progression.
• Cyclooxygenase-2 (Cox-2) plays a significant role in inflammation and tumor development.
• The herbal mixture KJS018A is derived from plants with known anti-cancer and anti-inflammatory properties.

Purpose of the Study:

• To investigate the inhibitory effects of KJS018A on liver cancer (hepatocarcinogenesis) and inflammation.
• To understand the molecular mechanisms underlying KJS018A's action.

Main Methods:

• Assessing KJS018A's impact on hepatic malignant cell proliferation.
• Measuring levels of Interleukin-6 (IL-6) and Cyclooxygenase-2 (Cox-2).
• Evaluating the modulation of the IL-6/STAT3/Cox-2 pathway and epithelial-mesenchymal transition markers (Twist, N-cadherin, MMP-9, E-cadherin).
• Utilizing immunohistochemistry to analyze tumor growth and marker expression in vivo.

Main Results:

• KJS018A significantly inhibited hepatic malignant cell proliferation.
• KJS018A downregulated IL-6 and Cox-2 levels, and diminished the inflammatory effects of PMA.
• The mixture suppressed cancer cell metastasis by altering key protein expressions and reduced tumor growth.
• KJS018A also reduced IL-6 and Cox-2 levels in tumor tissues.

Conclusions:

• KJS018A demonstrates significant anti-cancer and anti-inflammatory effects.
• The herbal mixture acts through the IL-6/STAT3/Cox-2 pathway and influences epithelial-mesenchymal transition.
• KJS018A shows potential for preventing inflammation-driven liver cancer.